Skip to main content
Skip to navigation
Research Exchange
Living Lab
Discovery Lab
Donate
HERTHENA-PanTumor01: a phase II study of patritumab deruxtecan (HER3-DXd) in previously treated advanced solid tumors
Thomas Powles & Hidetoshi Hayashi et al.
· 2025-10-14
Links
DOI
PubMed
Journal
Future Oncology
Institutions
Queen Mary University Of London
Yale Cancer Center
Cancer Institute Of New South Wales
Shikoku Cancer Center
National Cancer Center Hospital East
Roswell Park Comprehensive Cancer Center
University Of Iowa Holden Comprehensive Cancer Center
Sarah Cannon Research Institute
The University Of Texas Md Anderson Cancer Center
Memorial Sloan Kettering Cancer Center
Centre Lon Brard
Northwestern University
Merck France
Daiichi Sankyo Portugal
Kindai University
Authors
Thomas Powles
,
Aarti Bhatia
,
Barbara Burtness
,
Takahiro Kogawa
,
Tomohiro Nishina
,
Izuma Nakayama
,
Christos Fountzilas
,
Dani R. Castillo
,
Meredith McKean
,
Funda Meric-Bernstam
,
James W. Smithy
,
Jérome Fayette
,
Sunandana Chandra
,
Fan Jin
,
Graham Clinthorne
,
Ariel E. Aguilo
,
Hidetoshi Hayashi
Funding
Pathology
Daiichi Sankyo Company, Limited Funding
Merck Sharp & Dohme LLC Funding
NCI NIH HHS
P30 CA008748